Atopic dermatitis is a medical condition with active clinical research programs worldwide.

36 total trials for this combination

Showing top 10 of 36 trials

Trials

NCT ID	Title	Status	Phase
NCT01949311	Open-label Study of Dupilumab in Patients With Atopic Dermatitis	COMPLETED	PHASE3
NCT03738397	A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis	COMPLETED	PHASE3
NCT05724199	A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)	COMPLETED	PHASE3
NCT05882877	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)	ACTIVE_NOT_RECRUITING	PHASE3
NCT04392154	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	COMPLETED	PHASE3
NCT03587805	Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND	COMPLETED	PHASE3
NCT02260986	Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis	COMPLETED	PHASE3
NCT05601882	A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	COMPLETED	PHASE3
NCT03569293	Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)	COMPLETED	PHASE3
NCT02340234	A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis	COMPLETED	PHASE2

Related Pages

All Atopic dermatitis trials All trials in Waterloo, Canada